An advanced course on the regulatory mechanics of drug development—from IND submission through NDA/BLA approval and post-marketing obligations. This course equips clinical development leaders, regulatory strategists, and physician-scientists with the operational depth to navigate FDA, EMA, and global regulatory interactions: meeting preparation and negotiation, expedited pathway selection, submission planning, and lifecycle regulatory management. Where Course 1 introduced strategic decision-making across the development lifecycle and Course 2 covered protocol-level execution, this course goes deep on the regulatory process itself—how agencies think, what they expect, and how to build regulatory strategy as a competitive advantage. Content integrates ICH E6(R3) sponsor oversight principles, ICH E3 clinical study report requirements, CTD/eCTD submission format, and FDA/EMA guidance documents throughout. This is Course 3 of the Clinical Development Strategy learning track.
Explore the complete course structure before you enroll.
3 lessons · 135 min
1.1 Regulatory science and the regulatory state
How drug regulation evolved from reactive catastrophe response to proactive scientific assessment, the social contract between regulators and industry, and why understanding regulatory history is essential for effective regulatory strategy.
Create your free account to access the complete curriculum, knowledge assessments, and professional certificate.
An advanced course on the regulatory mechanics of drug development—from IND submission through NDA/BLA approval and post-marketing obligations. This course equips clinical development leaders, regulatory strategists, and physician-scientists with the operational depth to navigate FDA, EMA, and global regulatory interactions: meeting preparation and negotiation, expedited pathway selection, submission planning, and lifecycle regulatory management. Where Course 1 introduced strategic decision-making across the development lifecycle and Course 2 covered protocol-level execution, this course goes deep on the regulatory process itself—how agencies think, what they expect, and how to build regulatory strategy as a competitive advantage. Content integrates ICH E6(R3) sponsor oversight principles, ICH E3 clinical study report requirements, CTD/eCTD submission format, and FDA/EMA guidance documents throughout. This is Course 3 of the Clinical Development Strategy learning track.
Explore the complete course structure before you enroll.
3 lessons · 135 min
1.1 Regulatory science and the regulatory state
How drug regulation evolved from reactive catastrophe response to proactive scientific assessment, the social contract between regulators and industry, and why understanding regulatory history is essential for effective regulatory strategy.
Create your free account to access the complete curriculum, knowledge assessments, and professional certificate.
22 lessons · 7 quizzes · 11 hours of content
Part of the Clinical Development Strategy learning track
1.2 Major regulatory authorities
The organizational structures, review processes, and decision-making cultures of the world's major regulatory agencies—FDA (CDER/CBER), EMA (CHMP/CAT), PMDA, NMPA, Health Canada, and TGA—and how their differences shape global development planning.
1.3 ICH and global harmonization
The ICH organizational structure, guideline development process, CTD/eCTD submission format, and the strategic tension between global harmonization and regional regulatory divergence—including emerging convergence initiatives.
3 lessons · 135 min
2.1 Standard and expedited FDA pathways
The complete landscape of FDA regulatory pathways from standard review through Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, and RMAT, including eligibility criteria, procedural benefits, post-approval obligations, and the strategic calculus of pathway selection.
2.2 EMA and global expedited pathways
A comparative analysis of EMA expedited mechanisms---PRIME, conditional marketing authorization, accelerated assessment, and exceptional circumstances---alongside PMDA SAKIGAKE, Health Canada Priority Review and NOC/c, and TGA provisional approval, with a framework for designing coherent global expedited pathway strategies.
2.3 Orphan drug and pediatric regulatory strategy
A strategic analysis of orphan drug designation (FDA and EMA), pediatric regulatory requirements (PREA and PIPs), the Rare Pediatric Disease Priority Review Voucher program, and the unique regulatory, ethical, and operational challenges of developing therapies for rare diseases and pediatric populations.
3 lessons · 135 min
3.1 FDA meeting types and strategy
The complete taxonomy of FDA meeting types---Type A, B, and C---with deep focus on Pre-IND, End-of-Phase 2, and Pre-NDA/BLA meetings: meeting request packages, briefing document construction, question strategy, the 70-day timeline, and how to maximize the value of every agency interaction.
3.2 EMA scientific advice and global interactions
CHMP scientific advice and protocol assistance mechanisms, parallel FDA-EMA scientific advice programs, PMDA consultations, and the design of a global regulatory interaction strategy that synchronizes agency engagements across a development program timeline.
3.3 The art of regulatory negotiation
Negotiation principles for regulatory interactions---position preparation, understanding agency motivations, managing disagreements, clinical hold and refuse-to-file responses, formal dispute resolution at FDA and EMA, and strategies for building productive long-term agency relationships.
3 lessons · 135 min
4.1 IND structure and submission strategy
The architecture and content requirements of the IND under 21 CFR 312.23, pre-IND meeting strategy for aligning with FDA before submission, the 30-day safety review process, clinical hold criteria, cross-referencing approaches including right of reference and Drug Master Files, and strategic decisions in IND preparation and phased clinical program planning.
4.2 IND maintenance
The ongoing regulatory obligations of maintaining an active IND—protocol amendments, information amendments, the serial submission architecture, IND safety reporting under 21 CFR 312.32, aggregate safety analysis through the DSUR, annual report content and timing, and how the quality of IND maintenance shapes the pre-NDA relationship with the review division.
4.3 Regulatory compliance during development
GCP inspection readiness as a strategic imperative---FDA pre-approval inspections, routine surveillance, and for-cause inspections; the 483 observation and warning letter process with response strategies and escalation pathways; EMA GCP inspections and cross-jurisdictional compliance implications; and designing a proactive regulatory compliance strategy integrating CAPA frameworks, sponsor oversight documentation under ICH E6(R3), and quality management systems.
4 lessons · 180 min
5.1 NDA/BLA submission strategy
Designing the marketing application submission strategy---pathway selection confirmation, submission type determination (505(b)(1), 505(b)(2), BLA), Pre-NDA/BLA meeting objectives and execution, rolling submission tactics and eligibility, and the content plan across all five CTD modules with integration points between clinical, CMC, nonclinical, and regulatory publishing teams.
5.2 The clinical data package
Constructing the clinical component of the marketing application---integrated summaries of safety and efficacy, clinical study reports per ICH E3, clinical overview and clinical summary, clinical narrative strategy, and the data integrity standards that underpin reviewer confidence.
5.3 CMC and nonclinical contributions
Understanding the CMC and nonclinical components of the marketing application from the clinical development leader's perspective---manufacturing readiness, process validation timing, nonclinical pharmacology and toxicology contributions, CTD integration strategy, and how deficiencies in these modules trigger complete response letters.
5.4 Labeling strategy and advisory committee preparation
Designing the labeling strategy and preparing for FDA advisory committee meetings---USPI structure and negotiation, SmPC requirements, advisory committee mechanics and voting procedures, panel composition analysis, question anticipation, rehearsal strategies, and post-AdCom regulatory action.
3 lessons · 135 min
6.1 Post-marketing commitments and requirements
Distinguishing FDA PMRs from PMCs, evaluating REMS and EMA Risk Management Plans, understanding confirmatory trial obligations after accelerated approval, and designing strategic approaches to post-approval regulatory compliance.
6.2 Safety reporting and pharmacovigilance regulation
Analyzing post-marketing safety reporting requirements including ICSR timelines, PSUR/PBRER and DSUR frameworks, signal detection through FAERS and EudraVigilance, and designing integrated pharmacovigilance compliance strategies for marketed products.
6.3 Label changes, variations, and lifecycle regulatory strategy
Evaluating supplemental application strategies (sNDA/sBLA) and EMA variation procedures for label expansion, designing lifecycle regulatory strategies that coordinate new indications with exclusivity timelines, and analyzing the interplay between regulatory exclusivity and patent protection.
3 lessons · 135 min
7.1 Building the regulatory strategy document
Designing the regulatory strategy document as the integrative blueprint that connects target product profile, pathway selection, agency interaction planning, submission timelines, and risk mitigation into a single living artifact that drives the development program.
7.2 Competitive regulatory intelligence
Applying public regulatory databases, advisory committee transcripts, and agency review documents as competitive intelligence tools to inform endpoint selection, safety database expectations, comparator decisions, and overall development strategy.
7.3 Regulatory leadership and cross-functional integration
Synthesizing the regulatory strategist's leadership role within the cross-functional development team, strategies for building agency credibility, portfolio-level regulatory risk management, and an integrated view of how regulatory strategy creates competitive advantage throughout the drug development lifecycle.
22 lessons · 7 quizzes · 11 hours of content
Part of the Clinical Development Strategy learning track
1.2 Major regulatory authorities
The organizational structures, review processes, and decision-making cultures of the world's major regulatory agencies—FDA (CDER/CBER), EMA (CHMP/CAT), PMDA, NMPA, Health Canada, and TGA—and how their differences shape global development planning.
1.3 ICH and global harmonization
The ICH organizational structure, guideline development process, CTD/eCTD submission format, and the strategic tension between global harmonization and regional regulatory divergence—including emerging convergence initiatives.
3 lessons · 135 min
2.1 Standard and expedited FDA pathways
The complete landscape of FDA regulatory pathways from standard review through Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, and RMAT, including eligibility criteria, procedural benefits, post-approval obligations, and the strategic calculus of pathway selection.
2.2 EMA and global expedited pathways
A comparative analysis of EMA expedited mechanisms---PRIME, conditional marketing authorization, accelerated assessment, and exceptional circumstances---alongside PMDA SAKIGAKE, Health Canada Priority Review and NOC/c, and TGA provisional approval, with a framework for designing coherent global expedited pathway strategies.
2.3 Orphan drug and pediatric regulatory strategy
A strategic analysis of orphan drug designation (FDA and EMA), pediatric regulatory requirements (PREA and PIPs), the Rare Pediatric Disease Priority Review Voucher program, and the unique regulatory, ethical, and operational challenges of developing therapies for rare diseases and pediatric populations.
3 lessons · 135 min
3.1 FDA meeting types and strategy
The complete taxonomy of FDA meeting types---Type A, B, and C---with deep focus on Pre-IND, End-of-Phase 2, and Pre-NDA/BLA meetings: meeting request packages, briefing document construction, question strategy, the 70-day timeline, and how to maximize the value of every agency interaction.
3.2 EMA scientific advice and global interactions
CHMP scientific advice and protocol assistance mechanisms, parallel FDA-EMA scientific advice programs, PMDA consultations, and the design of a global regulatory interaction strategy that synchronizes agency engagements across a development program timeline.
3.3 The art of regulatory negotiation
Negotiation principles for regulatory interactions---position preparation, understanding agency motivations, managing disagreements, clinical hold and refuse-to-file responses, formal dispute resolution at FDA and EMA, and strategies for building productive long-term agency relationships.
3 lessons · 135 min
4.1 IND structure and submission strategy
The architecture and content requirements of the IND under 21 CFR 312.23, pre-IND meeting strategy for aligning with FDA before submission, the 30-day safety review process, clinical hold criteria, cross-referencing approaches including right of reference and Drug Master Files, and strategic decisions in IND preparation and phased clinical program planning.
4.2 IND maintenance
The ongoing regulatory obligations of maintaining an active IND—protocol amendments, information amendments, the serial submission architecture, IND safety reporting under 21 CFR 312.32, aggregate safety analysis through the DSUR, annual report content and timing, and how the quality of IND maintenance shapes the pre-NDA relationship with the review division.
4.3 Regulatory compliance during development
GCP inspection readiness as a strategic imperative---FDA pre-approval inspections, routine surveillance, and for-cause inspections; the 483 observation and warning letter process with response strategies and escalation pathways; EMA GCP inspections and cross-jurisdictional compliance implications; and designing a proactive regulatory compliance strategy integrating CAPA frameworks, sponsor oversight documentation under ICH E6(R3), and quality management systems.
4 lessons · 180 min
5.1 NDA/BLA submission strategy
Designing the marketing application submission strategy---pathway selection confirmation, submission type determination (505(b)(1), 505(b)(2), BLA), Pre-NDA/BLA meeting objectives and execution, rolling submission tactics and eligibility, and the content plan across all five CTD modules with integration points between clinical, CMC, nonclinical, and regulatory publishing teams.
5.2 The clinical data package
Constructing the clinical component of the marketing application---integrated summaries of safety and efficacy, clinical study reports per ICH E3, clinical overview and clinical summary, clinical narrative strategy, and the data integrity standards that underpin reviewer confidence.
5.3 CMC and nonclinical contributions
Understanding the CMC and nonclinical components of the marketing application from the clinical development leader's perspective---manufacturing readiness, process validation timing, nonclinical pharmacology and toxicology contributions, CTD integration strategy, and how deficiencies in these modules trigger complete response letters.
5.4 Labeling strategy and advisory committee preparation
Designing the labeling strategy and preparing for FDA advisory committee meetings---USPI structure and negotiation, SmPC requirements, advisory committee mechanics and voting procedures, panel composition analysis, question anticipation, rehearsal strategies, and post-AdCom regulatory action.
3 lessons · 135 min
6.1 Post-marketing commitments and requirements
Distinguishing FDA PMRs from PMCs, evaluating REMS and EMA Risk Management Plans, understanding confirmatory trial obligations after accelerated approval, and designing strategic approaches to post-approval regulatory compliance.
6.2 Safety reporting and pharmacovigilance regulation
Analyzing post-marketing safety reporting requirements including ICSR timelines, PSUR/PBRER and DSUR frameworks, signal detection through FAERS and EudraVigilance, and designing integrated pharmacovigilance compliance strategies for marketed products.
6.3 Label changes, variations, and lifecycle regulatory strategy
Evaluating supplemental application strategies (sNDA/sBLA) and EMA variation procedures for label expansion, designing lifecycle regulatory strategies that coordinate new indications with exclusivity timelines, and analyzing the interplay between regulatory exclusivity and patent protection.
3 lessons · 135 min
7.1 Building the regulatory strategy document
Designing the regulatory strategy document as the integrative blueprint that connects target product profile, pathway selection, agency interaction planning, submission timelines, and risk mitigation into a single living artifact that drives the development program.
7.2 Competitive regulatory intelligence
Applying public regulatory databases, advisory committee transcripts, and agency review documents as competitive intelligence tools to inform endpoint selection, safety database expectations, comparator decisions, and overall development strategy.
7.3 Regulatory leadership and cross-functional integration
Synthesizing the regulatory strategist's leadership role within the cross-functional development team, strategies for building agency credibility, portfolio-level regulatory risk management, and an integrated view of how regulatory strategy creates competitive advantage throughout the drug development lifecycle.